Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: a meta-analysis

Area of Science:

• Pharmacology
• Nephrology
• Clinical Medicine

Background:

• Enoxaparin's elimination half-life and accumulation increase with declining glomerular filtration rate (GFR).
• Dose adjustments for enoxaparin are recommended for GFR <30 ml/min and considered relatively safe.

Purpose of the Study:

• To evaluate the safety of enoxaparin use in patients with GFR <60 ml/min.
• To determine the impact of enoxaparin dose adjustment on bleeding risk in patients with impaired kidney function.

Main Methods:

• A systematic literature search and meta-analysis of controlled trials comparing enoxaparin with other anticoagulants.
• Analysis focused on studies where enoxaparin dosage was specified and the primary endpoint was major bleeding.

Main Results:

• Enoxaparin use in patients with GFR <60 ml/min was associated with a significant increase in major bleeding complications (RR 1.67, p=0.01).
• Bleeding risk escalated exponentially with decreasing GFR across chronic kidney disease stages (CKD 1-5).
• Even with dose adjustments, enoxaparin significantly increased major bleeding risk in patients with GFR <60 ml/min compared to those with GFR >60 ml/min.

Conclusions:

• Enoxaparin treatment is considered safe only for patients with a GFR >60 ml/min.
• Current dose adjustment strategies do not sufficiently mitigate the increased bleeding risk in patients with moderate to severe kidney dysfunction.